{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:28:34Z","timestamp":1782941314842,"version":"3.54.5"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Transgender women (assigned male at birth) usually take antiandrogens associated with estrogens (or are castrated) to induce feminization, whereas transgender men (assigned female at birth) take testosterone to induce masculinization. However, the cardiovascular outcomes of these gender-affirming hormone therapies (GAHTs) remain poorly studied.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the association between GAHT intake and cardiac repolarization alterations on electrocardiography in transgender individuals.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this cohort study, data from a prospective cohort of adult transgender individuals from a single center in France were collected from January 1, 2021, to January 1, 2023. GAHT consisted of injectable testosterone in transgender men and transdermal estradiol with mostly oral cyproterone acetate as antiandrogens in transgender women.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Electrocardiographic features, including QTc, T-wave maximal amplitude (TAmp), and QT peak (QTp; distance between Q onset and T peak), were studied. Circulating sex hormones, including total testosterone, estradiol, progesterone, and gonadotrophins, were assessed concomitantly to electrocardiographic intake.<\/jats:p><\/jats:sec>Results<\/jats:title>In the overall cohort of 120 transgender individuals (mean [SD] age, 29.7 [11.9] years; 64 transgender men and 56 transgender women), mean (SD) QTc was similar between 35 transgender women receiving GAHT (406\u2009[20] milliseconds) and 23 transgender men before GAHT (400\u2009[16] milliseconds) but prolonged vs 41 transgender men receiving GAHT (378\u2009[19] milliseconds) (P<\/jats:italic>\u2009&amp;lt;\u2009.001) or 21 transgender women before receiving GAHT (384\u2009[21] milliseconds) (P<\/jats:italic>\u2009&amp;lt;\u2009.001). The start of GAHT in 15 transgender women was associated with increased QTc (mean [SD], 20\u2009[12] milliseconds vs before receiving GAHT; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and decreased QTc in 18 transgender men (mean [SD], \u221217\u2009[16] milliseconds vs before receiving GAHT; P<\/jats:italic>\u2009&amp;lt;\u2009.001). No participant had a QTc greater than 480 milliseconds or QTc change greater than 60 milliseconds after the start of GAHT in this study. Nonlinear mixed models (eg, integrating age, calcemia, relevant circulating hormones levels, and torsadogenic drug intake) showed that QTc was associated with total testosterone in transgender men (mean [SD] estimate, \u22121.6\u2009[0.6] ms\/ng\/mL; P<\/jats:italic>\u2009=\u2009.007) and prolactin (mean [SD], 0.4\u2009[0.1] ms\/ng\/mL; P<\/jats:italic>\u2009&amp;lt;\u2009.001). In transgender women, QTc was associated with total testosterone (mean [SD] estimate, \u22123.5\u2009[0.8] ms\/ng\/mL; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Variation of QTp and TAmp observed after the start of GAHT and associated hormonal alteration were globally associated with those observed with QTc, although in opposite directions for transgender women and transgender men.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, testosterone use in transgender men was associated with QTc and QTp shortening and increased TAmp. Androgen deprivation in transgender women was associated with opposite observations. The magnitude of QTc sexual dimorphism seen in cisgender adults was also observed in the transgender population. This work highlights that potential GAHT effects on cardiac repolarization warrant attention in the exponentially increasing transgender population, which is often exposed to coprescribed drugs prolonging QTc and at risk of TdP.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.24124","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:31:10Z","timestamp":1753889470000},"page":"e2524124","source":"Crossref","is-referenced-by-count":3,"title":["Transgender-Affirming Hormone Therapies, QT Prolongation, and Cardiac Repolarization"],"prefix":"10.1001","volume":"8","author":[{"given":"Virginie","family":"Grouthier","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Centre Hospitalier Universitaire de Bordeaux, Haut-Leveque Hospital, F-33604 Pessac, France"},{"name":"University of Bordeaux, Inserm U1034, Biology of Cardiovascular Diseases, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Matamala","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Centre Hospitalier Universitaire de Bordeaux, Haut-Leveque Hospital, F-33604 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Centre Hospitalier Universitaire de Bordeaux, Haut-Leveque Hospital, F-33604 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Galioot","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Centre Hospitalier Universitaire de Bordeaux, Haut-Leveque Hospital, F-33604 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Couffinhal","sequence":"additional","affiliation":[{"name":"University of Bordeaux, Inserm U1034, Biology of Cardiovascular Diseases, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Vaglio","sequence":"additional","affiliation":[{"name":"AMPS LLC, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Badilini","sequence":"additional","affiliation":[{"name":"AMPS LLC, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Prifti","sequence":"additional","affiliation":[{"name":"Unit for Mathematical and Computer Modeling of Complex Systems, Institut de Recherche Pour le D\u00e9veloppement, Sorbonne University, Bondy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[{"name":"INSERM, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Clinical Investigation Center (CIC) 1901, Department of Pharmacology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"zoi250688r1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8.","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"issue":"7","key":"zoi250688r2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jamasurg.2017.6231","article-title":"Temporal trends in gender-affirming surgery among transgender patients in the United States.","volume":"153","author":"Canner","year":"2018","journal-title":"JAMA Surg"},{"issue":"6","key":"zoi250688r3","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1161\/CIR.0000000000001003","article-title":"Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association.","volume":"144","author":"Streed","year":"2021","journal-title":"Circulation"},{"issue":"19","key":"zoi250688r4","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1161\/CIR.0000000000000914","article-title":"Assessing and addressing cardiovascular health in LGBTQ adults: a scientific statement from the American Heart Association.","volume":"142","author":"Caceres","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"zoi250688r5","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1093\/cvr\/cvab288","article-title":"Cardiovascular disease in transgender people: recent research and emerging evidence.","volume":"117","author":"Connelly","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"6","key":"zoi250688r6","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/HYPERTENSIONAHA.119.13080","article-title":"Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults.","volume":"74","author":"Connelly","year":"2019","journal-title":"Hypertension"},{"issue":"4","key":"zoi250688r7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study.","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi250688r8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1530\/EJE-14-0011","article-title":"Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.","volume":"170","author":"Gooren","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"8-9","key":"zoi250688r9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.acvd.2016.12.011","article-title":"Fast, accurate and easy-to-teach QT interval assessment: the triplicate concatenation method.","volume":"110","author":"Saqu\u00e9","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"issue":"10","key":"zoi250688r10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval.","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"issue":"38","key":"zoi250688r11","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehab588","article-title":"Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome.","volume":"42","author":"Prifti","year":"2021","journal-title":"Eur Heart J"},{"issue":"38","key":"zoi250688r12","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi250688r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181875","article-title":"GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, \u201cGENEREPOL study\u201d: lack of common variants with large effect sizes.","volume":"12","author":"Salem","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"zoi250688r14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cpt.896","article-title":"Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the \u201cCiPA\u201d initiative and design of a prospective clinical validation study.","volume":"103","author":"Vicente","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi250688r15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","article-title":"Hypogonadism as a reversible cause of torsades de pointes in men.","volume":"138","author":"Salem","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"zoi250688r16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamacardio.2018.2251","article-title":"Association of oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women.","volume":"3","author":"Salem","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"13","key":"zoi250688r17","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/CIRCULATIONAHA.119.041395","article-title":"Effect of transdermal testosterone and oral progesterone on drug-induced QT interval lengthening in older men: a randomized, double-blind, placebo-controlled crossover-design study.","volume":"140","author":"Muensterman","year":"2019","journal-title":"Circulation"},{"key":"zoi250688r18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","article-title":"Influence of steroid hormones on ventricular repolarization.","volume":"167","author":"Salem","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"7","key":"zoi250688r19","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1210\/jc.2016-1877","article-title":"Complex influence of gonadotropins and sex steroid hormones on QT interval duration.","volume":"101","author":"Abehsira","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"zoi250688r20","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1136\/heartjnl-2017-312934","article-title":"Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.","volume":"104","author":"Grouthier","year":"2018","journal-title":"Heart"},{"issue":"5","key":"zoi250688r21","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/cvr\/cvz020","article-title":"Cardiac arrhythmia considerations of hormone cancer therapies.","volume":"115","author":"Barber","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"13","key":"zoi250688r22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","article-title":"Androgenic effects on ventricular repolarization: a translational study from the International Pharmacovigilance Database to iPSC-Cardiomyocytes.","volume":"140","author":"Salem","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"zoi250688r23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.122.063156","article-title":"Beyond sex-based medicine in cardiovascular health research and practice.","volume":"147","author":"Beach","year":"2023","journal-title":"Circulation"},{"issue":"2","key":"zoi250688r25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","article-title":"CredibleMeds.org: what does it offer?","volume":"28","author":"Woosley","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"zoi250688r26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling.","volume":"45","author":"Garnett","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"zoi250688r27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1210\/jc.2008-1902","article-title":"The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men.","volume":"94","author":"Brambilla","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"zoi250688r28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1152\/japplphysiol.00346.2023","article-title":"Menstrual cycle hormones and oral contraceptives: a multimethod systems physiology-based review of their impact on key aspects of female physiology.","volume":"135","author":"D\u2019Souza","year":"2023","journal-title":"J Appl Physiol (1985)"},{"issue":"7","key":"zoi250688r29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1515\/CCLM.2006.160","article-title":"Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer.","volume":"44","author":"Stricker","year":"2006","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"zoi250688r30","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/ijms22031464","article-title":"Sexual dimorphisms, anti-hormonal therapy and cardiac arrhythmias.","volume":"22","author":"Grouthier","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"zoi250688r31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.echo.2017.10.017","article-title":"Complex association of sex hormones on left ventricular systolic function: insight into sexual dimorphism.","volume":"31","author":"Salem","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"zoi250688r32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14779072.2019.1606713","article-title":"Cardiac arrhythmias secondary to hormone therapy in trans women.","volume":"17","author":"Wamboldt","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"7","key":"zoi250688r33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jacep.2016.02.015","article-title":"Influence of oral progesterone administration on drug-induced QT interval lengthening: a randomized, double-blind, placebo-controlled crossover study.","volume":"2","author":"Tisdale","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"zoi250688r34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/joa3.12360","article-title":"Burden of arrythmias in transgender patients hospitalized for gender-affirming surgeries.","volume":"36","author":"Antwi-Amoabeng","year":"2020","journal-title":"J Arrhythm"},{"issue":"15","key":"zoi250688r35","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/eurjpc\/zwac133","article-title":"Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy.","volume":"29","author":"Karalexi","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"zoi250688r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3994","article-title":"Effect of feminizing hormone therapy on QTc interval: a secondary analysis of a randomized clinical trial.","volume":"7","author":"Angus","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi250688r37","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.19102\/icrm.2019.100202","article-title":"Brugada syndrome unmasked by use of testosterone in a transgender male: gender trumps sex as a risk factor.","volume":"10","author":"Sichrovsky","year":"2019","journal-title":"J Innov Card Rhythm Manag"},{"issue":"5","key":"zoi250688r38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/healthcare11050705","article-title":"Prevalence and determinants of depressive and anxiety symptoms among transgender people: results of a survey.","volume":"11","author":"Hajek","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"zoi250688r39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jad.2020.05.074","article-title":"Increased prevalence of depression, anxiety, and adjustment and somatoform disorders in transsexual individuals.","volume":"274","author":"Konrad","year":"2020","journal-title":"J Affect Disord"},{"issue":"7","key":"zoi250688r40","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/europace\/euz037","article-title":"Postpartum hormones oxytocin and prolactin cause pro-arrhythmic prolongation of cardiac repolarization in long QT syndrome type 2.","volume":"21","author":"Bodi","year":"2019","journal-title":"Europace"},{"key":"zoi250688r24","unstructured":"ClinicalTrials.gov. Protocol Trans and QT Repolarization. NCT05865262. Accessed June 11, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05865262"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2836920\/grouthier_2025_oi_250688_1753200001.14483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:31:11Z","timestamp":1753889471000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2836920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.24124","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}